{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T18:27:49Z","timestamp":1766428069691},"reference-count":45,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2003,11,14]],"date-time":"2003-11-14T00:00:00Z","timestamp":1068768000000},"content-version":"vor","delay-in-days":2357,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aliment Pharmacol Ther"],"published-print":{"date-parts":[[1997,6]]},"abstract":"<jats:sec><jats:title>Background:<\/jats:title><jats:p>This meta\u2010analysis investigated factors that may affect the risk of relapse of oesophagitis, and evaluated the predictive value of symptoms for the presence of relapse during long\u2010term treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods:<\/jats:title><jats:p>Individual data from 1154 patients included in five independently conducted, randomized, long\u2010term clinical trials of the efficacy of different dosage regimens of omeprazole, standard ranitidine treatment and placebo for the prevention of relapse of oesophagitis were pooled for this meta\u2010analysis. The therapeutic regimens studied were omeprazole 20\u2003mg o.m. (OME20) in 366 patients, omeprazole 10\u2003mg o.m. (OME10) in 225 patients, omeprazole 20\u2003mg weekends (OMEW) in 235 patients, ranitidine 150\u2003mg b.d. (RAN) in 179 patients, or placebo (PLA) in 149 patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results:<\/jats:title><jats:p>OME20 maintained 82.4% (95% CI: 78.2\u201386.6%) of patients in endoscopic remission over the 6\u2010month period compared to 71.9% (95% CI: 65.5\u201378.3%) for OME10, 52.3% (95% CI: 44.4\u201360.1%) for RAN, 42.7% (95% CI: 35.8\u201349.5%) for OMEW, and 10.6% (95% CI: 5.0\u201316.3%) for PLA. A Cox's regression analysis of time to recurrence of oesophagitis showed that four factors were associated with a higher relapse rate during placebo and active maintenance therapy: (a) pre\u2010treatment severity of oesophagitis (<jats:italic>P<\/jats:italic>&lt;0.0001), (b) young age (<jats:italic>P<\/jats:italic>=0.01), (c) non\u2010smoking (<jats:italic>P<\/jats:italic>=0.02) and (d) moderate\/severe regurgitation before entry into the trials (<jats:italic>P<\/jats:italic>=0.03). Asymptomatic relapse of oesophagitis was uncommon, being found in only 8.6% of the patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions:<\/jats:title><jats:p>Maintenance treatment with omeprazole 10 and 20\u2003mg daily is superior to all other regimens tested, and is only marginally influenced by the pre\u2010treatment severity of oesophagitis. Age contributes to the factors that influence the outcome during long\u2010term treatment with omeprazole. Symptom relief is highly predictive for the maintenance of healing.<\/jats:p><\/jats:sec>","DOI":"10.1046\/j.1365-2036.1997.00167.x","type":"journal-article","created":{"date-parts":[[2003,11,14]],"date-time":"2003-11-14T11:46:44Z","timestamp":1068810404000},"page":"473-482","source":"Crossref","is-referenced-by-count":108,"title":["Prognostic factors influencing relapse of oesophagitis during maintenance therapy with antisecretory drugs: a meta\u2010analysis of long\u2010term omeprazole trials"],"prefix":"10.1111","volume":"11","author":[{"given":"R.","family":"Carlsson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.\u2010P.","family":"Galmiche","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Dent","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Lundell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Frison","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2003,11,14]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"crossref","unstructured":"RichterJEDyspepsia: Organic causes and differential characteristics from functional dyspepsia. Scand J Gastroenterol1991;11(Suppl. 182):11\u20136.","DOI":"10.3109\/00365529109109531"},{"key":"e_1_2_1_3_2","doi-asserted-by":"crossref","unstructured":"BrunnenPL KarmodyAM NeedhamCDSevere peptic oesophagitis. Gut1969;11:831\u20137.","DOI":"10.1136\/gut.10.10.831"},{"key":"e_1_2_1_4_2","doi-asserted-by":"crossref","unstructured":"L\u00f6\u00f6fL G\u00f6tellP ElfbergBThe incidence of reflux esophagitis. A study of endoscopy reports from a defined catchment area in Sweden. Scand J Gastroenterol1993;11:113\u20138.","DOI":"10.3109\/00365529309096056"},{"key":"e_1_2_1_5_2","doi-asserted-by":"crossref","unstructured":"SonnenbergAEpidemiologie und Spontanverlauf der Reluxkrankheit. In: Blum AL Siewert JR eds. Refluxtherapie. Berlin: Springer Verlag 1981: 85\u2013106.","DOI":"10.1007\/978-3-642-67714-4_6"},{"key":"e_1_2_1_6_2","doi-asserted-by":"crossref","unstructured":"Wienbeck\u2003M&BarnertJEpidemiology of reflux disease and reflux esophagitis. Scand J Gastroenterol1989;11(Suppl. 156):7\u201313.","DOI":"10.3109\/00365528909091032"},{"key":"e_1_2_1_7_2","unstructured":"SpechlerSEpidemiology and natural history of gastroesophageal reflux disease. Digestion1992;11(Suppl. 1):24\u20139."},{"key":"e_1_2_1_8_2","doi-asserted-by":"crossref","unstructured":"DentJRoles of gastric acid and pH\u2003in the pathogenesis of gastro\u2010oesophageal reflux disease. Scand J Gastroenterol1994;11(Suppl. 201):55\u201361.","DOI":"10.3109\/00365529409105365"},{"key":"e_1_2_1_9_2","doi-asserted-by":"crossref","unstructured":"MascleeAAM De BestACAM De GraafR CluysenaerOJJ JansenJBMJAmbulatory 24\u2010hour pH\u2010metry in the diagnosis of gastroesophageal reflux disease. Determination of criteria and relation to endoscopy. Scand J Gastroenterol1990;11:225\u201330.","DOI":"10.1080\/00365521.1990.12067095"},{"key":"e_1_2_1_10_2","doi-asserted-by":"crossref","unstructured":"GalmicheJ\u2010P&JanssensJThe pathophysiology of gastro\u2010oesophageal reflux disease: An overview. Scand J Gastroenterol1995;11(Suppl. 211):7\u201318.","DOI":"10.3109\/00365529509090286"},{"key":"e_1_2_1_11_2","doi-asserted-by":"crossref","unstructured":"FiorruciS SantucciL PerroneE AbbrittiF MorelliAGastric and esophageal acidity during continuous treatment with H2\u2010antagonists in uncomplicated esophagitis. Scand J Gastroenterol1989;11:671\u20137.","DOI":"10.3109\/00365528909093107"},{"key":"e_1_2_1_12_2","unstructured":"OrlandoRCPathophysiology of gastroesophageal reflux disease: Esophageal epithelial resistance. In: Castell DO ed. The Esophagus. Boston Toronto London: Little Brown and Company 1992: 463\u201378."},{"key":"e_1_2_1_13_2","doi-asserted-by":"crossref","unstructured":"VaeziMF SinghS RichterJERole of acid and duodenogastric reflux in esophageal mucosal injury: A review of animal and human studies. Gastroenterology 1995; 108: 1987\u20131907.","DOI":"10.1016\/0016-5085(95)90156-6"},{"key":"e_1_2_1_14_2","doi-asserted-by":"crossref","unstructured":"Klinkenberg\u2010KnolEC JansenJMBJ FestenHPM MeuwissenSGM LamersCBHWDouble\u2010blind multicentre comparison of omeprazole and ranitidine in the treatment of reflux oesophagitis. Lancet1987; i: 349\u201351.","DOI":"10.1016\/S0140-6736(87)91726-0"},{"key":"e_1_2_1_15_2","doi-asserted-by":"crossref","unstructured":"HetzelDJ DentJ ReedWD et al. Healing and relapse of severe peptic esophagitis after treatment with omeprazole. Gastroenterology 1988;11:903\u201312.","DOI":"10.1016\/0016-5085(88)90162-X"},{"key":"e_1_2_1_16_2","doi-asserted-by":"crossref","unstructured":"HavelundT LaursenLS Skoubo\u2010KristensenE et al.Omeprazole and ranitidine in the treatment of reflux oesophagitis. Br Med J1988;11:89\u201392.","DOI":"10.1136\/bmj.296.6615.89"},{"key":"e_1_2_1_17_2","doi-asserted-by":"crossref","unstructured":"VantrappenG RutgeertsL SchurmansP CoenegrachtsJLOmeprazole (40\u2003mg) is superior to ranitidine in the short term treatment of ulcerated reflux esophagitis. Dig Dis Sci1988;11:523\u20139.","DOI":"10.1007\/BF01798351"},{"key":"e_1_2_1_18_2","doi-asserted-by":"crossref","unstructured":"SandmarkS CarlssonR FausaO LundellLOmeprazole or ranitidine in the treatment of reflux esophagitis. Results from a double\u2010blind randomized multicentre study. Scand J Gastroenterol1988;11:625\u201332.","DOI":"10.3109\/00365528809093923"},{"key":"e_1_2_1_19_2","unstructured":"ZeitounP RampalP BarbierP IsalJ\u2010P ErikssonS CarlssonROmeprazole (20\u2003mg o.m.) vs. ranitidine (150\u2003mg b.i.d.) in reflux esophagitis. Results of a double\u2010blind randomized trial. Gastroenterol Clin Biol1989;11:457\u201362."},{"key":"e_1_2_1_20_2","doi-asserted-by":"crossref","unstructured":"BateCM KeelingPWN O'MorainCO et al. Comparison of omeprazole and cimetidine in reflux oesophagitis: symptomatic endoscopic and histological evaluations. Gut1990;11:968\u201372.","DOI":"10.1136\/gut.31.9.968"},{"key":"e_1_2_1_21_2","unstructured":"BateCM CroweJP DickinsonRJ et al. Reflux oesophagitis resolves more rapidly with omeprazole 20\u2003mg once daily than with ranitidine 150\u2003mg twice daily: Omeprazole 40\u2003mg once daily provides further benefit in unresponsive patients. Br J Clin Res1991;11:133\u201348."},{"key":"e_1_2_1_22_2","doi-asserted-by":"crossref","unstructured":"SontagSJ HirschowitzBI HoltS et al.Two doses of omeprazole vs. placebo in symptomatic erosive esophagitis: The U.S. multicenter study. Gastroenterology1992;11:109\u201318.","DOI":"10.1016\/0016-5085(92)91790-B"},{"key":"e_1_2_1_23_2","doi-asserted-by":"crossref","unstructured":"HatlebakkJG BerstadA CarlingL et al.Lansoprazole vs. omeprazole in short\u2010term treatment of reflux oesophagitis: Results of a Scandinavian multicentre trial. Scand J Gastroenterol1993;11:224\u20138.","DOI":"10.3109\/00365529309096076"},{"key":"e_1_2_1_24_2","unstructured":"Feldman\u2003M HarfordWV FisherRS et al. Treatment of reflux esophagitis resistant to H2\u2010receptor antagonists with lansoprazole a new H+\/K+\u2010ATPase inhibitor: A controlled double\u2010blind study. Am J Gastroenterol1993;11:1212\u20137."},{"key":"e_1_2_1_25_2","doi-asserted-by":"crossref","unstructured":"BaderJP&DelchierJCClinical efficacy of pantoprazole compared with ranitidine. Aliment Pharm Ther1994;11(Suppl. 1):47\u201352.","DOI":"10.1111\/j.1365-2036.1994.tb00247.x"},{"key":"e_1_2_1_26_2","unstructured":"ZeitounP BarbierP CayphasJ\u2010P IsalJ\u2010P CarlssonRcomparison of two dosage regimens of omeprazole\u201410\u2003mg once daily and 20\u2003mg weekends\u2014as prophylaxis against recurrence of reflux esophagitis. Hepatogastroenterol1989;11:279\u201380(Abstract)."},{"key":"e_1_2_1_27_2","doi-asserted-by":"crossref","unstructured":"Staerk LaursenL HavelundT BondesenS et al.Omeprazole in the long\u2010term treatment of gastro\u2010oesophageal reflux disease. A double\u2010blind randomized dose\u2010finding study. Scand J Gastroenterol1995;11:839\u201346.","DOI":"10.3109\/00365529509101589"},{"key":"e_1_2_1_28_2","unstructured":"SontagS Robinson\u2003M Roufail\u2003W et al.Daily omeprazole (OME) is needed to maintain healing in erosive esophagitis (EE): A U.S. multicenter double\u2010blind study. Am J Gastroenterol1992; 87: A1258(Abstract)."},{"key":"e_1_2_1_29_2","doi-asserted-by":"crossref","unstructured":"DentJ YeomansN Mackinnon\u2003M et al.Omeprazole vs. ranitidine for prevention of relapse in reflux oesophagitis. A controlled double\u2010blind trial of their efficacy and safety. Gut1994;11:590\u20138.","DOI":"10.1136\/gut.35.5.590"},{"key":"e_1_2_1_30_2","doi-asserted-by":"crossref","unstructured":"Hallerb\u00e4ckB UngeP CarlingL et al.Omeprazole or ranitidine in long\u2010term treatment of reflux esophagitis. Gastroenterology1994;11:1305\u201311.","DOI":"10.1016\/0016-5085(94)90531-2"},{"key":"e_1_2_1_31_2","doi-asserted-by":"crossref","unstructured":"CoxDRRegression models and life tables. J Royal Stat Soc1972;B11:187\u2013220.","DOI":"10.1111\/j.2517-6161.1972.tb00899.x"},{"key":"e_1_2_1_32_2","unstructured":"PocockSClinical trials. Chichester England: Wiley 1983: 221\u20137."},{"key":"e_1_2_1_33_2","doi-asserted-by":"crossref","unstructured":"BellNJ&HuntRHRole of gastric acid suppression in the treatment of gastro\u2010oesophageal reflux disease. Gut1992;11:118\u201324.","DOI":"10.1136\/gut.33.1.118"},{"key":"e_1_2_1_34_2","doi-asserted-by":"crossref","unstructured":"BateCM BoothSN CroweJP et al. Omeprazole 10\u2003mg or 20\u2003mg once daily in the prevention of recurrence of reflux oesophagitis. Gut1995;11:492\u20138.","DOI":"10.1136\/gut.36.4.492"},{"key":"e_1_2_1_35_2","doi-asserted-by":"crossref","unstructured":"JohnssonF JoelssonB Gudmundsson\u2003K GreiffLSymptoms and endoscopic findings in the diagnosis of gastroesophageal reflux. Scand J Gastroenterol1987;11:714\u20138.","DOI":"10.3109\/00365528709011148"},{"key":"e_1_2_1_36_2","doi-asserted-by":"crossref","unstructured":"KlauserAG SchindlbeckNE M\u00fcller\u2010LissnerSASymptoms in gastro\u2010oesophageal reflux disease. Lancet1990;11:205\u20138.","DOI":"10.1016\/0140-6736(90)90287-F"},{"key":"e_1_2_1_37_2","unstructured":"GreenJRBIs there such an entity as mild oesophagitis? Eur J Clin Res1993;11:29\u201334."},{"key":"e_1_2_1_38_2","doi-asserted-by":"crossref","unstructured":"LandahlS AnderssonT Larsson\u2003M et al.Pharmacokinetic study of omeprazole in elderly healthy volunteers. Clin Pharmacokinet1992;11:469\u201376.","DOI":"10.2165\/00003088-199223060-00006"},{"key":"e_1_2_1_39_2","doi-asserted-by":"crossref","unstructured":"DennishGW&CastellDOInhibitory effect of smoking on the lower esophageal sphincter. N Engl J Med1971;11: 1136.","DOI":"10.1056\/NEJM197105202842007"},{"key":"e_1_2_1_40_2","doi-asserted-by":"crossref","unstructured":"StanciuC&BennettJRSmoking and gastro\u2010oesophageal reflux. Br Med J1972;11: 793.","DOI":"10.1136\/bmj.3.5830.793"},{"key":"e_1_2_1_41_2","doi-asserted-by":"crossref","unstructured":"KoelzHR BirchlerR BretholtzA et al.Healing and relapse of reflux esophagitis during treatment with ranitidine. Gastroenterology1986;11:1198\u2013205.","DOI":"10.1016\/S0016-5085(86)80017-8"},{"key":"e_1_2_1_42_2","doi-asserted-by":"crossref","unstructured":"KusterE RosE Toledo\u2010PimentelV et al.Predictive factors of the long term outcome in gastro\u2010oesophageal reflux disease: six year follow up of 107 patients. Gut1994;11:8\u201314.","DOI":"10.1136\/gut.35.1.8"},{"key":"e_1_2_1_43_2","doi-asserted-by":"crossref","unstructured":"JoelssonB&JohnssonFHeartburn the acid test. Gut1989;11:1523\u20135.","DOI":"10.1136\/gut.30.11.1523"},{"key":"e_1_2_1_44_2","doi-asserted-by":"crossref","unstructured":"Ruth\u2003M EnbomH LundellL L\u00f6nrothH SandbergN SandmarkSThe effect of omeprazole or ranitidine treatment on 24\u2010hour esophageal acidity in patients with reflux esophagitis. Scand J Gastroenterol1988;11:1141\u20136.","DOI":"10.3109\/00365528809090182"},{"key":"e_1_2_1_45_2","unstructured":"FiorucciS SantucciL MorelliAEffect of omeprazole and high doses of ranitidine on gastric acidity and gastroesophageal reflux in patients with moderate\u2013severe esophagitis. Am J Gastroenterol1990;11:1458\u201362."},{"key":"e_1_2_1_46_2","doi-asserted-by":"crossref","unstructured":"SchindlbeckNE KlauserAG VoderholzerWA M\u00fcller\u2010LissnerSAMean acidity or percentage reflux time in oesophageal pH\u2010monitoring. Eur J Gastroenterol Hepatol1993;11:155\u20139.","DOI":"10.1097\/00042737-199303000-00006"}],"container-title":["Alimentary Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2036.1997.00167.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1365-2036.1997.00167.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,27]],"date-time":"2023-10-27T13:55:37Z","timestamp":1698414937000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1046\/j.1365-2036.1997.00167.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1997,6]]},"references-count":45,"journal-issue":{"issue":"3","published-print":{"date-parts":[[1997,6]]}},"alternative-id":["10.1046\/j.1365-2036.1997.00167.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1365-2036.1997.00167.x","archive":["Portico"],"relation":{},"ISSN":["0269-2813","1365-2036"],"issn-type":[{"value":"0269-2813","type":"print"},{"value":"1365-2036","type":"electronic"}],"subject":[],"published":{"date-parts":[[1997,6]]}}}